Affordable Access

Publisher Website

Short-term therapy with peroxisome proliferation-activator receptor-alpha agonist Wy-14,643 protects murine fatty liver against ischemia-reperfusion injury.

Authors
Type
Published Article
Journal
Hepatology
1527-3350
Publisher
Wiley Blackwell (John Wiley & Sons)
Publication Date
Volume
51
Issue
3
Pages
996–1006
Identifiers
DOI: 10.1002/hep.23420
PMID: 20131406
Source
Medline

Abstract

NASH and SS livers are both more susceptible to IRI. Mechanisms include possible distortion of the microvasculature by swollen fat-laden hepatocytes, and enhanced production of several cytokines. The beneficial effects of Wy-14,643 may be exerted by dampening adhesion molecule and cytokine responses, and activating NF-kappaB, IL-6 production, and p38 kinase to effect cell cycle entry.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments